Nuclear receptors in vascular biology by Bishop-Bailey, D
 1 
 
RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE 
 
This is the author’s accepted manuscript of the following article: 
Bishop-Bailey, D (2015) Nuclear receptors in vascular biology. Current Atherosclerosis 
Reports, 17(27). 
The final publication is available at Springer via http://dx.doi.org/10.1007/s11883-015-0507-
8.  
The full details of the published version of the article are as follows: 
 
TITLE: Nuclear receptors in vascular biology  
AUTHORS: David Bishop-Bailey 
JOURNAL TITLE: Current Atherosclerosis Reports  
VOLUME/EDITION: 17/27 
PUBLICATION DATE: 15 March 2015 (online) 
PUBLISHER: Current Medicine Group 
DOI: 10.1007/s11883-015-0507-8  
 
1 
 
  
 
 
Nuclear Receptors in Vascular Biology 
 
 
David Bishop-Bailey, BSc, PhD 
Comparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 
0TU, United Kingdom 
 
Email: dbishopbailey@rvc.ac.uk 
Tel: +44 20 7468 5505 
 
 
 
Word count: 2768 
 
Key words: steroid, vitamin, atherosclerosis, endothelial, xenobiotic 
 
 
 
 
 
 
2 
 
Abstract 
Nuclear receptors sense a diverse group of steroids and hormones (estrogens, progesterone, 
androgens, glucocorticoid and mineralocorticoid), vitamins (A and D), lipid metabolites, 
carbohydrates and xenobiotics. In response to these diverse but critically important mediators, 
nuclear receptors regulate the homeostatic control of lipids, carbohydrate, cholesterol and 
xenobiotic drug metabolism, inflammation, cell differentiation and development, including vascular 
development. The nuclear receptor family is one of the most important groups of signaling molecules 
in the body, and as such represent some of the most important established and emerging clinical and 
therapeutic targets. This review will highlight some of the emerging trends in nuclear receptor 
biology related to vascular biology. 
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Introduction  
In man, the nuclear receptor family consists of 48 ligand activated-transcription factors [1]. 
For the purpose of this review I have subdivided these in to 5 functional groups: 1) the hormone/ 
steroid and related family, 2) the fat soluble vitamin and related family, 3) the nutritional and related 
family, 4) the xenobiotic sensing receptors and 5) the orphan / atypical receptors (Table 1). The 
majority of nuclear receptors have only recently been identified and remain orphan i.e. with no 
known endogenous ligand(s) [1]. Since, established sex, steroid, and vitamin nuclear receptors play 
such critical roles and are important clinical targets, there has been a great interest in elucidating the 
expression and function of orphan nuclear receptors. Our understanding of the great importance of 
nuclear receptors was initially based on only a few of these receptors (e.g. the steroid family) which 
have well-established ligands/ activators and roles throughout the body.  
The vasculature is the interface between the circulation and underlying tissue, and as such is 
exposed to all the known nuclear receptor activators. Endothelial cells play a key role in 
cardiovascular homeostasis but are integral to all organ function. The endothelium has clear roles in 
blood pressure, regulating thrombosis, inflammation, transport and oxygen supply. A potentially 
important point of regulation of the vasculature could therefore be via nuclear receptors which are 
activated by circulating hormones, steroids, xenobiotics, and vitamins as well as other dietary 
nutrients including lipids and carbohydrates [1, 2]. Since the mid 1999’s there has been a great 
interest in nuclear receptors in vascular biology. From a relatively small level of understanding that a 
number of steroid family members were expressed (estrogen [ER], glucocorticoid [GR], androgen 
[AR], mineralocorticoid [MR] and retinoic acid receptor [RAR]s) a functional role for a great number 
of vascular nuclear receptors including peroxisome proliferator activated receptors (PPAR-
, farnesoid X receptor (FXR), the small heterodimer partner (SHP), the pregnane X 
receptor (PXR), retinoid X receptors RXR and -, the constitutive androsterone receptor (CAR), 
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neuronal growth factor-induced clone B (NGFI-B)s, retinoic acid receptor-related orphan receptor 
(ROR)s, estrogen-related receptor (ERR)s and chicken ovalbumin upstream promoter-transcription 
factor (COUP-TF)s nuclear receptors have all been found expressed in vascular cells or tissue (Table 
1, Table 2 and Figure 1A; [1]).  
With the emergence of large scale omic strategies (e.g. gene array) signals for a large number 
of nuclear receptors (EAR-2 (COUP-TF), COUP-TF, liver X receptor (LXR), ERR, testicular orphan 
receptors (TR)2, ROR, TR4, COUP-TF, AR, liver receptor homologue (LRH)-1, RAR, MR, GR, thyroid 
receptor (TR), REV-ERB, ROR, steroidogenic factor (SF)-1, and TR have been identified (table 2; 
figure 1; [2]). These data highlight that there is still very limited information (SHP, REV-ERB, COUP-
TF, TR, ThR, VDR) or no information (ERR, GCNF, TR, HNF4) for vascular roles for many of these 
nuclear receptors. It must also me noted that these gene array studies, although useful, are not 
definitive and have several limitations, in that i) studies from tissue such as whole intact heart and 
aorta are unlikely to reveal any clear information regarding expression of nuclear receptors in a single 
rarer cell populations e.g. endothelial cells; ii) steady-state mRNA levels of any nuclear receptor does 
not necessarily correlate well to steady-state protein levels or importantly receptor activity; and iii) 
receptor levels may change upon cell activation. For three of the lowest level receptors indicated, 
PPAR FXR, PXR (table 2) they already have a confirmed vascular cell expression [3-6].  
This review aims to introduce the nuclear receptor family as an important family of 
therapeutically relevant signaling molecules and discuss the recent trends in their research in 
vascular biology, in particular to relation to cardiovascular diseases.   
 
Nuclear receptor mode of action 
Nuclear receptors are grouped as a family due to their structural similarity. The template for the 
nuclear receptor is a variable n-terminal AF-1 region, a relatively well conserved DNA binding domain, 
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a small hinge region, a ligand binding domain, and a c-terminal AF-2 domain which is often required 
for ligand dependent receptor activation [7]. There are several molecular mechanisms by which 
nuclear receptors are believed to act, however very little is still known about the potential for 
vascular specific actions. Nuclear receptors act in large complexes to induce transcription, trans-
suppression and act vi non-genomic mechanisms: 
Transcription: Nuclear receptors act in large dynamic complexes, commonly as homodimers 
or heterodimers (commonly with RXRs). Upon agonist treatment, nuclear receptors from a repressed 
protein complex undergo a conformational change and recruit a variety of activator proteins that are 
critical to initiate gene transcription i.e. genomic signalling [8]. Classically this co-activator complex 
involves the binding of the ‘AF-2’ c-terminal end of the ligand binding domain of the nuclear receptor 
to a LXXLL peptide sequence in the nuclear receptor co-activator [8]. The specificity of these nuclear 
receptor dimers in inducing target gene transcription is considered to be due to subtle differences in 
‘response elements’ binding sites in target gene promoters. Nuclear receptors have a response 
elements based on repeats (e.g. direct or inverted), separated by different lengths of nucleotides of 
the sequence “AGGTCA”.  
Trans-suppression: Nuclear receptors can also trans-suppress gene activation independent of 
transcription e.g. the glucocorticoid receptor can directly bind and inhibit NFB. Recently, a particular 
post-translational modification of nuclear receptors, SUMOylation, was identified as critical for many 
trans-suppression pathways. Ligand dependent SUMOylation of PPAR or LXR mediates the anti-
inflammatory effects of these receptors by physically stabilizing pro-inflammatory transcription 
factors in a co-repressor complex [9], while SUMOylation of LRH-1 in the liver can lead to increased 
atherosclerosis in atheroprone mice due repression of reverse cholesterol transport [10]. 
Non-genomic: There is increasing evidence, including studies in anucleated platelets that 
nuclear receptors can act in a rapid DNA-independent manner. RXR, RXR, PPAR, PPAR and the 
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glucocorticoid receptor are present and rapidly inhibit platelet activation [11-14]. RXR was found 
to rapidly bind and inhibit the heterotrimeric G-protein Gq in a ligand dependent manner, potentially 
through the presence of an LXXLL motif found in the Gq family [14].  
 Nuclear receptors have great structural similarity particularly those of close family 
members, how they act to induce distinct but sometimes overlapping gene programs and functional 
effects is however far from clear. The role of co-regulators is clearly important [15] and may give cell 
and target specificity for a nuclear receptor. Well over 100 different proteins are known to interact 
with nuclear receptors, as co-activators, co-suppressors, and molecular chaperones (see the Nuclear 
receptor signalling atlas; http://www.nursa.org/). Figure 1C highlights some of the most highly 
expressed in human endothelial cells. Although less is known about these nuclear receptor- co-
regulator interactions in vascular cells, in macrophages the PPARγ coactivator (PGC)-1α was recently 
found to be a target for the anti-atherosclerotic actions of conjugated linoleic acid [16], while BLC6 
release from a complex with PPAR appears responsible for many anti-inflammatory actions of 
PPAR ligands in this cell type [17]. An additional emerging area also is the potential for nuclear 
receptor interaction with microRNA (miRNA)s. miRNAs are a family of a small non-coding RNA 
molecules which can silence mRNAs and regulate gene expression in a post-transcriptional manner 
[18]. Again recent data from macrophages indicate that activation of PPARγ inhibits the expression 
of miR-613 which in turn alleviates a suppression on LXRα and ABCA1 to promote reverse cholesterol 
transport [19]. 
 
New trends for nuclear receptors in regulating vascular biology: 
There has been a great interest in particular in nutritional receptors including PPARs LXRs, FXR and 
RAR/ RXRs . These receptors have been reviewed extensively elsewhere. Here therefore the focus 
will be on the re-emergence of 1) steroid hormones and related receptors, 2) the emergence of 
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vascular xenobiotic receptors as novel vascular targets, and 3) orphan/ atypical receptors.  
 
Steroid hormones and related receptors 
The evidence that pre-menopausal women are protected from cardiovascular disease has long 
implicated the balance of the sex hormones estrogens and androgens in cardiovascular health [20-
22]. ER, ER [20] and AR [23] are expressed in vascular tissue. New evidence supports both a 
protective role for estrogen in vascular tissue, but also highlights a detrimental role for androgen 
signaling in macrophages, but not necessarily vascular cells in atherosclerosis development. 
 Proteases inhibitor use such as ritonavir commonly used to treat HIV is commonly associated with 
a profound dyslipidaemia [24]. Experimentally ritonavir increased coronary artery wall thickness and 
foam cell formation, which was associated with a down-regulation of ERα and Erβ, and reversed by 
addition of estradiol [25]. Moreover, ritonavir could be seen to directly bind ERα and inhibit its 
nuclear translocation (essential for its transcriptional activity) [25]. 
 In contrast, Huang et al., have been studying the cell specific roles of androgens and the AR in 
atherosclerosis development [26]. Monocyte/macrophage specific AR knockout, endothelial cell 
specific-AR knockout, and smooth muscle cell specific -AR knockout mice were generated by cre-lox 
and then crossed with atheroprone LDLR knockout mice. Monocyte/macrophage specific AR 
knockout mice, or targetting AR degradation with a pharmacological agent ASC-J9 had reduced 
atherosclerosis compared with wild-type-LDLR knockout control mice, whereas endothelial cell and 
smooth muscle cell AR knockout mice were similar to control LDLR knockout mice[26].  
 The role of mineralocorticoid activation of MR to regulate aldosterone and blood pressure 
are well established. Moreover, MR inhibitors clinically reduced the incidence of cardiovascular 
events and improve mortality rates [27]. MR is also expressed in vascular endothelial cells and 
smooth muscle cells [27]. Smooth muscle cell MR activation causes vasoconstriction and promotes 
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vessel inflammation, fibrosis, and remodeling [27]. In a model of high fat feeding induced endothelial 
cell dysfunction, endothelial cell expression of NADPH oxidase (subunits p22phox, p40phox), and 
impaired endothelial cell-dependent vasodilation were reversed by either an MR antagonist 
(eplerenone), or in endothelial cells specific MR knockout mice [28]. 
 Steroid receptors clearly have dramatic whole body actions including on metabolic pathways. 
These studies are also highlighting their expression in vascular tissue and are pointing to roles of 
these receptors directly in cell types relevant to the development of atherosclerosis. 
 
Xenobiotic receptors  
PXR is a nuclear receptor that has a highly promiscuous ligand binding domain, acting as a common 
drug, hormone, and nutrient sensor that co-ordinates detoxification and elimination pathways in the 
liver [29]. Although a number of PXR-regulated enzymes such as CYP3A and 2C are among the 
numerous CYPs expressed in vascular cells [30, 31], virtually nothing was known about the expression 
or relevance of PXR in vascular tissue. Recently published [5] results show that human primary 
vascular endothelial and smooth muscle cells express PXR and respond to PXR activation resulting in 
a cyto-protective, repair and anti-inflammatory phenotype; raising the possibility that vascular 
homeostasis in humans is directly influenced by this receptor. Given that the vasculature is an organ 
system estimated to have a mass equivalent to that of the liver [32] vascular PXR could play a pivotal 
role in whole body as well as in local vascular protection. In addition to vascular cells, PXR is also 
known to be expressed in human monocytes and T-lymphocytes [33]. Recent studies show PXR 
activation limits pro-inflammatory responses in monocytes and CD4+ T-cells (using cells isolated from 
the humanised PXR mouse; [34]) 
 PXR in its role as a metabolic sensor, can be activated and regulate the activity of an array of drugs 
with high relevance to the cardiovascular system. PXR is activated by synthetic glucocorticoids; 
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dihydropyridine calcium channel blockers [35], statins [36], environmental contaminants (e.g. 
polychlorinated biphenyls; [36]), and cholesterol metabolites (e.g. oxysterols); all of which that have 
been implicated in atherosclerosis development [37, 38]. In addition, PXR promotes the CYP3A4-
dependent biotransformation of clopidogrel to its active metabolite, thus promoting its inhibitory 
action on platelet aggregation [39]. Through PXR activation vascular tissue was able to convert the 
inactive pro-drug clopidogrel to its active metabolite [5]. A number of these findings were recently 
confirmed in vitro and in vivo [40] and extended to show that PXR activity is up-regulated in regions 
of laminar shear stress (athero-protected) but depressed with oscillatory shear stress (pro-
atherogenic) in the mouse [40]. 
 Despite the demonstration that PXR has protective roles in human vascular cells [5], studies in 
mouse models (particularly the mouse knockout) are far more inconsistent. PXR-apoE double 
knockout mice have a reduced atherosclerotic burden [41, 42] and PXR-ob/ob mice or PXR knockouts 
on a high-fat diet show increased obesity and insulin resistance [43]. A strong note of caution must 
however be made when interpreting the PXR knockout mouse, as distinct functional differences are 
found between murine and human PXR in the humanized-PXR mouse and in animal models where 
pharmacological drug responses have been observed. Humanized-PXR mice are resistant to high-fat 
diet-induced obesity, similar to that found in PXR knockout mice [44], findings that are consistent 
with a protective function for human PXR and that question the value of interpreting the previous 
knockout mouse studies as relevant to humans. In further support of a protective role for PXR, 
pharmacological activation using St John’s Wort extract (containing the potent PXR activator 
hyperforin) improved lipid profiles and reduced atherosclerosis in the high-fat fed rabbit [45]. 
Similarly, pharmacological PXR activation in obesity prone AKR/J mice prevents high-fat diet-induced 
obesity and insulin resistance [46]. In contrast, Bisphenol A appears to increase atherosclerotic 
burden in the humanized PXR-apo knockout mouse (Bisphenol A increases atherosclerosis in 
10 
 
pregnane X receptor-humanized ApoE deficient mice [47]. Which if any of these in vivo studies 
truly represent the actions of PXR in humans with atherosclerosis is therefore far from clear. It is also 
conceivable that different activators may have different actions in different and the same tissue using 
the same nuclear receptor. What has emerged however is that the vasculature is a dynamic site for 
drug metabolism pathways via PXR. 
 
Orphan/ atypical nuclear receptors. 
Although much less is known about the orphan / atypical nuclear receptors, this is one of the most 
exciting areas of research. For example, COUP-TF family members, in particular COUP-TFII, is critical 
for vascular development [48]. COUP-TFII is expressed in the tissues in all major physiological 
systems: central nervous system (CNS), endocrine, metabolic, gastrointestinal, immune, 
reproductive, cardiovascular, respiratory and structural; with particularly high levels in the adrenal 
gland, kidney, ovary, uterus and vas deferens. COUP-TFII is vital for organogenesis, particularly of the 
vascular system [48, 49]. In mouse models, targeted deletion of COUP-TFII produces non-viable 
embryos with the heart atria and sinus venosus unable to develop past the primitive tube stage [48]. 
In addition the re-modelling of the capillary plexus into large and small micro-capillaries is defective. 
Conditional knockouts of COUP-TF II have additionally revealed a role in widespread organogenesis 
including venous programming and vein identity [50], insulin secretion and sensitivity [51], stomach 
development [52], adipogenesis [51], male fertility [53], and limb and skeletal muscle development 
[54].  
 Of increasing recent interest has been the NGFI-B (NR4A) family of nuclear receptors [55]. 
This family of nuclear receptors has clear roles in immune cell selection and development [55]. NGFI-
B (Nur77; NR4A1), NGFI-Bb (Nurr1; NR4A2), reduce whereas NOR-1 (NR4A3) exacerbates 
atherosclerotic vascular lesions in mice [55]. Targetting macrophage NGFI-B (Nur77) activation in 
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macrophages either by pharmacological activation or overexpression reduces atherosclerosis in apoE 
knockout mice [56]. NGFI-B/Nur77 also appears to be directly anti-inflammatory in vascular cells as 
in vitro, NGFI-B/Nur77 is expressed in human endothelial cells and when activated or overexpressed 
inhibits the production of the potent vasoconstrictor endothelin-1 via suppression of the AP-1 
transcription factor [57]. 
 
Conclusion 
The nuclear receptor family represents one of the most clinically important therapeutic targets e.g. 
glucorticoids, estrogens, progesterones etc. 48 nuclear receptors exist in man; however we still no 
relatively little about a number of these targets and their endogenous ligands.  We do now know the 
vasculature contains a vast number of these receptors where they not only provide valuable 
information about the role of the vasculature in physiology and homeostatic processes, but have 
provided avenues of research for new drugs. Over the last 20 years a number of these receptors have 
been targeted with varying degrees of success for therapeutic treatment of cardiovascular diseases.  
Over the next 20 we are sure to see continuing advances in the field and increasing numbers of ways 
to target this important set of signaling molecules. 
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Table 1: The nuclear receptor subfamily sub-divided in to activators 
Steroid & related Estrogen receptor , -, progesterone receptor, androgen 
receptor, glucocorticoid receptor, mineralocorticoid 
receptor, estrogen-related receptor , 
steroidogenic factor-1, thyroid hormone receptor   
Vitamin & related Retinoic acid receptor-, vitamin D receptor, retinoid 
X receptor-, retinoic acid receptor-related orphan 
receptor- 
Nutritional & related Peroxisome proliferator-activated receptor-, liver X 
receptor-, farnesoid X receptor, small heterodimer 
partner, hepatocyte nuclear factor 4, liver receptor 
homologue-1 
Xenobiotic pregnane X receptor, constitutive androsterone receptor 
Orphan / atypical chicken ovalbumin upstream promoter-transcription factor-I, 
-II, -II, germ cell nuclear factor, photoreceptor cell-specific 
nuclear receptor, RevErbA, tailless homologue, 
testicular receptor-2 and -4 
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Table 2: Mouse cardiovascular (heart and aorta) nuclear receptor mRNA abundance (modified from 
ref [2]). Historical abbreviations have been used. 1indicates receptors identified in human or rat 
vascular cells and tissue. Italics indicates an orphan receptor. 
Absent Low  Moderate   High 
CAR1 
DAX-1 
FXR 
HNF4a 
PNR 
PXR1 
TLX 
AR 
ER1 
FXR1 
GCNF 
HNF4 
LRH-1 
PPAR1 
ROR 
SHP1 
SF1 
TR2 
 
VDR 
COUP-TF 
COUP-TF 
ER 
ERR 
ERR 
GR 
LXR 
MR 
NOR1 
NURR1 
PPAR1 
PPAR1 
PR 
RAR  
RAR 
RAR 
REV-ERB 
REV-ERB 
ROR 
RXR1 
TR4 
COUP-TF 
ERR 
LXR 
NGFIB 
ROR 
RXR1 
RXR1 
TR 
AR, androgen receptor, CAR, constitutive androstane receptor, COUP-TF, chicken ovalbumin upstream promoter-transcription factor I, 
Dax-1, dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome, gene, ER, -, estrogen receptor 
ERR, estrogen-related receptor, FXR, farnesoid X receptor, GCNF, germ cell nuclear factor, GR, glucocorticoid receptor HNF4, 
hepatocyte nuclear factor 4, LRH-1, liver receptor homologue, LXR, liver X receptor, MR, mineralocorticoid receptor, NGFI-B, 
neuronal growth factor-induced clone B, PNR, photoreceptor cell-specific nuclear receptor, PPAR, peroxisome proliferator activated 
receptors, PR, progesterone receptor, PXR/SXR, pregnane X receptor/ steroid and xenobiotic receptor, RAR, retinoic acid receptor, 
RevErbA, ROR, retinoic acid receptor-related Orphan Receptor, RXR, retinoid X receptors, SF-1, steroidogenic factor, 
SHP, small heterodimer partner, ThR, thyroid hormone receptor, TLL, TLX or tailless, TR-2, -4, testicular orphan receptors, TR, thyroid 
receptor, VDR, vitamin D receptor. 
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Figure 1. Nuclear receptors in the vasculature. (A) Schematic of known nuclear receptors (central 
cluster), their activators (left cluster) and physiological roles (right cluster). (B) the correlation (r2=0.6; 
p<0.05) between raw Illumina signals for nuclear receptors in the primary human aortic endothelial 
cells and human umbilical vein endothelial cells; (C) Raw illumine signals for the top 10 ‘expressed’ 
nuclear receptor co-regulators in human primary aortic endothelial cells; mean of n=4 for each cell 
type.  
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